Literature DB >> 9648154

DNA analysis at p53 locus in carcinomas arising from pleomorphic adenomas of salivary glands: comparison of molecular study and p53 immunostaining.

Y Yamamoto1, Y Kishimoto, I I Wistuba, A K Virmani, F Vuitch, A F Gazdar, J Albores-Saavedra.   

Abstract

Where and how frequently p53 abnormalities are involved in the development of pleomorphic adenoma (PA) and its malignant progression to carcinoma was investigated. The presence of p53 gene abnormalities was analyzed in eight patients with carcinoma in pleomorphic adenoma (CPA) by polymerase chain reaction (PCR)-based assays and immunohistochemistry. Normal salivary gland tissue, adenomatous, transitional and carcinomatous areas were microdissected from archival microslides and analyzed for allelic deletions of the p53 gene using two microsatellite markers at the p53 locus; dinucleotide (CA)n repeat and pentanucleotide (AAAAT)n repeat. Loss of heterozygosity (LOH) of the p53 gene was detected in 57% of adenomas, 86% of transitional lesions and 86% of carcinomas. In contrast, overexpression of p53 oncoprotein was noted immunohistochemically in 13% of adenomas, 50% of transitional areas and 75% of carcinomas. All of the tumors with immunoreactivity for p53 oncoprotein demonstrated LOH. Moreover, when LOH was present in adenomatous or transitional areas, the identical LOH was always detected in the corresponding carcinomatous areas in the same CPA tumors. These findings indicate that p53 gene mutation is an early event and occurs frequently at an early stage of precancerous lesions and may be responsible for most cases of malignant transformation of PA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648154     DOI: 10.1111/j.1440-1827.1998.tb03904.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.

Authors:  R C Ribeiro; F Sandrini; B Figueiredo; G P Zambetti; E Michalkiewicz; A R Lafferty; L DeLacerda; M Rabin; C Cadwell; G Sampaio; I Cat; C A Stratakis; R Sandrini
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

2.  Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study.

Authors:  Saori Matsubayashi; Toshio Yoshihara
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-20       Impact factor: 2.503

3.  Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma.

Authors:  Bassel Tarakji; Omar Kujan; Mohammad Z Nassani
Journal:  J Cancer Epidemiol       Date:  2010-12-28

4.  Carcinoma ex pleomorphic adenoma of the salivary glands: distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation.

Authors:  Jeong Won Kim; Gui Young Kwon; Jong-Lyel Roh; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim; Kyung-Ja Cho
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

Review 5.  A Review of Selected Factors of Salivary Gland Tumour Formation and Malignant Transformation.

Authors:  Pawel Sowa; Karolina Goroszkiewicz; Joanna Szydelko; Joanna Chechlinska; Katarzyna Pluta; Wojciech Domka; Maciej Misiolek; Wojciech Scierski
Journal:  Biomed Res Int       Date:  2018-08-01       Impact factor: 3.411

6.  Establishment and characterization of pleomorphic adenoma cell systems: an in-vitro demonstration of carcinomas arising secondarily from adenomas in the salivary gland.

Authors:  Satoshi Maruyama; Jun Cheng; Susumu Shingaki; Takashi Tamura; Shuichi Asakawa; Shinsei Minoshima; Yoshiko Shimizu; Nobuyoshi Shimizu; Takashi Saku
Journal:  BMC Cancer       Date:  2009-07-21       Impact factor: 4.430

7.  Canine mammary mixed tumours: a review.

Authors:  Geovanni Dantas Cassali; Angélica Cavalheiro Bertagnolli; Enio Ferreira; Karine Araújo Damasceno; Conrado de Oliveira Gamba; Cecília Bonolo de Campos
Journal:  Vet Med Int       Date:  2012-10-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.